Beyond gene therapy, other pharmacological approaches, such as glucagon-like peptide-1 receptor agonists (GLP-1 RAs), are being explored for their potential benefits in retinal diseases, including diabetic retinopathy [231]. The gene discussed is GLP1R; the disease is diabetic retinopathy.